{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:12:31Z","timestamp":1791357151819,"version":"4.3.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T00:00:00Z","timestamp":1372809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40272-013-0036-2","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T05:02:38Z","timestamp":1372741358000},"page":"505-514","source":"Crossref","is-referenced-by-count":56,"title":["Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial"],"prefix":"10.1007","volume":"15","author":[{"given":"Ali","family":"Ghaleiha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effat","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Modabbernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibeh","family":"Yekehtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,3]]},"reference":[{"issue":"5","key":"36_CR1","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1542\/peds.2007-2361","volume":"120","author":"CP Johnson","year":"2007","unstructured":"Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics. 2007;120(5):1183\u2013215.","journal-title":"Pediatrics"},{"key":"36_CR2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0074-7742(05)71013-8","volume":"71","author":"HH Cohly","year":"2005","unstructured":"Cohly HH, Panja A. Immunological findings in autism. Gaba Autism Relat Disord. 2005;71:317\u201341.","journal-title":"Gaba Autism Relat Disord"},{"issue":"7","key":"36_CR3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.tins.2006.05.010","volume":"29","author":"AM Persico","year":"2006","unstructured":"Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006;29(7):349\u201358.","journal-title":"Trends Neurosci"},{"issue":"3","key":"36_CR4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/1073858406298918","volume":"13","author":"JB Manent","year":"2007","unstructured":"Manent JB, Represa A. Neurotransmitters and brain maturation: early paracrine actions of GABA and glutamate modulate neuronal migration. Neuroscientist. 2007;13(3):268\u201379.","journal-title":"Neuroscientist"},{"issue":"5","key":"36_CR5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0387-7604(95)00079-Q","volume":"17","author":"MV Johnston","year":"1995","unstructured":"Johnston MV. Neurotransmitters and vulnerability of the developing brain. Brain Dev. 1995;17(5):301\u20136.","journal-title":"Brain Dev."},{"issue":"3","key":"36_CR6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.pnpbp.2007.11.004","volume":"32","author":"SH Fatemi","year":"2008","unstructured":"Fatemi SH. The hyperglutamatergic hypothesis of autism. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):911 (author reply 2-3).","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"36_CR7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/092986709787002745","volume":"16","author":"RL Blaylock","year":"2009","unstructured":"Blaylock RL, Strunecka A. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. Curr Med Chem. 2009;16(2):157\u201370.","journal-title":"Curr Med Chem"},{"issue":"8","key":"36_CR8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.pnpbp.2006.06.013","volume":"30","author":"A Shinohe","year":"2006","unstructured":"Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuro Psychopharmacol Biol Psychiatry. 2006;30(8):1472\u20137.","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"36_CR9","doi-asserted-by":"crossref","unstructured":"Shimmura C, Suda S, Tsuchiya KJ, Hashimoto K, Ohno K, Matsuzaki H, et al. Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. Plos One. 2011;6(10): e25340","DOI":"10.1371\/journal.pone.0025340"},{"issue":"3","key":"36_CR10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.mp.4000979","volume":"7","author":"S Jamain","year":"2002","unstructured":"Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, et al. Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry. 2002;7(3):302\u201310.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"36_CR11","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1542\/peds.113.5.e472","volume":"113","author":"R Muhle","year":"2004","unstructured":"Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113(5):e472\u201386.","journal-title":"Pediatrics"},{"issue":"3","key":"36_CR12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10578-007-0084-3","volume":"39","author":"S Akhondzadeh","year":"2008","unstructured":"Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Human Dev. 2008;39(3):237\u201345.","journal-title":"Child Psychiatry Human Dev"},{"issue":"6","key":"36_CR13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","volume":"40","author":"BH King","year":"2001","unstructured":"King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658\u201365.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"36_CR14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","volume":"34","author":"V Rezaei","year":"2010","unstructured":"Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress Neuro-Psychopharmacol Biol Psychiatry. 2010;34(7):1269\u201372.","journal-title":"Progress Neuro-Psychopharmacol Biol Psychiatry"},{"key":"36_CR15","doi-asserted-by":"crossref","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2012; 3:CD001447.","DOI":"10.1002\/14651858.CD001447.pub3"},{"issue":"3","key":"36_CR16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0014-2999(93)90037-I","volume":"250","author":"D Martin","year":"1993","unstructured":"Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol. 1993;250(3):473\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"36_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/B:CEMN.0000012717.37839.07","volume":"24","author":"ME Frizzo","year":"2004","unstructured":"Frizzo ME, Dall\u2019Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24(1):123\u20138.","journal-title":"Cell Mol Neurobiol"},{"issue":"6 Suppl 4","key":"36_CR18","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","volume":"47","author":"A Doble","year":"1996","unstructured":"Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(6 Suppl 4):S233\u201341.","journal-title":"Neurology"},{"issue":"4","key":"36_CR19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.npp.1301178","volume":"32","author":"J Du","year":"2007","unstructured":"Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology. 2007;32(4):793\u2013802.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"36_CR20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12031-012-9724-6","volume":"48","author":"J Cheng","year":"2012","unstructured":"Cheng J, Dong J, Cui Y, Wang L, Wu B, Zhang C. Interacting partners of AMPA-type glutamate receptors. J Mol Neurosci. 2012;48(2):441\u20137.","journal-title":"J Mol Neurosci"},{"issue":"5","key":"36_CR21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4155\/fmc.10.27","volume":"2","author":"IR Mellor","year":"2010","unstructured":"Mellor IR. The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities. Future Med Chem. 2010;2(5):877\u201391.","journal-title":"Future Med Chem"},{"issue":"9","key":"36_CR22","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1212\/WNL.57.9.1618","volume":"57","author":"AE Purcell","year":"2001","unstructured":"Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001;57(9):1618\u201328.","journal-title":"Neurology"},{"issue":"10","key":"36_CR23","doi-asserted-by":"crossref","first-page":"e25340","DOI":"10.1371\/journal.pone.0025340","volume":"6","author":"C Shimmura","year":"2011","unstructured":"Shimmura C, Suda S, Tsuchiya KJ, Hashimoto K, Ohno K, Matsuzaki H, et al. Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. PLoS ONE. 2011;6(10):e25340.","journal-title":"PLoS ONE"},{"issue":"2 Suppl","key":"36_CR24","first-page":"245","volume":"94","author":"G Schwartz","year":"2001","unstructured":"Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg. 2001;94(2 Suppl):245\u201356.","journal-title":"J Neurosurg"},{"issue":"2","key":"36_CR25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0006-8993(03)03343-2","volume":"989","author":"Y Gilgun-Sherki","year":"2003","unstructured":"Gilgun-Sherki Y, Panet H, Melamed E, Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res. 2003;989(2):196\u2013204.","journal-title":"Brain Res"},{"issue":"9","key":"36_CR26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/17425255.4.9.1223","volume":"4","author":"CA Zarate","year":"2008","unstructured":"Zarate CA, Manji HK. Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol. 2008;4(9):1223\u201334.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"36_CR27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/cap.2010.0009","volume":"20","author":"P Grant","year":"2010","unstructured":"Grant P, Song JY, Swedo SE. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010;20(4):309\u201315.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"36_CR28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/cap.2007.0021","volume":"17","author":"P Grant","year":"2007","unstructured":"Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007;17(6):761\u20137.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"36_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/15622970109026809","volume":"2","author":"R Gross-Isseroff","year":"2001","unstructured":"Gross-Isseroff R, Hermesh H, Weizman A. Obsessive compulsive behaviour in autism\u2014towards an autistic-obsessive compulsive syndrome? World J Biol Psychiatry. 2001;2(4):193\u20137.","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"36_CR30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/cap.2009.0087","volume":"20","author":"J Veenstra-VanderWeele","year":"2010","unstructured":"Veenstra-VanderWeele J. Increase in valproic acid levels during riluzole treatment in an adolescent with autism. J Child Adolesc Psychopharmacol. 2010;20(2):163\u20135.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"36_CR31","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/S0924-9338(09)70745-X","volume":"24","author":"L Wachtel","year":"2009","unstructured":"Wachtel L. P01\u2013124 Riluzole for affective and behavioral disturbance in autism. Eur Psychiatry. 2009;24:S512.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"36_CR32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/cap.2010.0154","volume":"21","author":"LK Wink","year":"2011","unstructured":"Wink LK, Erickson CA, Stigler KA, McDougle CJ. Riluzole in autistic disorder. J Child Adolesc Psychopharmacol. 2011;21(4):375\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"36_CR33","volume-title":"Diagnostic criteria from DSM-IV-TR","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000."},{"issue":"5","key":"36_CR34","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485\u201391.","journal-title":"Am J Ment Defic"},{"issue":"5","key":"36_CR35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","volume":"24","author":"C Lord","year":"1994","unstructured":"Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659\u201385.","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"36_CR36","first-page":"809","volume":"21","author":"CK Conners","year":"1985","unstructured":"Conners CK, Barkley RA. Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull. 1985;21(4):809\u201343.","journal-title":"Psychopharmacol Bull"},{"key":"36_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pnpbp.2009.09.012","volume":"34","author":"S Akhondzadeh","year":"2010","unstructured":"Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, Ghanizadeh A, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34:32\u20136.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"36_CR38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10578-012-0292-3","volume":"43","author":"E Hasanzadeh","year":"2012","unstructured":"Hasanzadeh E, Mohammadi MR, Ghanizadeh A, Rezazadeh SA, Tabrizi M, Rezaei F, et al. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Human Dev. 2012;43:674\u201382.","journal-title":"Child Psychiatry Human Dev"},{"key":"36_CR39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-012-2796-8","volume":"225","author":"M Asadabadi","year":"2013","unstructured":"Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacol (Berl). 2013;225:51\u20139.","journal-title":"Psychopharmacol (Berl)"},{"key":"36_CR40","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1017\/S1461145712000880","volume":"16","author":"A Ghaleiha","year":"2013","unstructured":"Ghaleiha A, Asadabadi M, Mohammadi MR, Shahei M, Tabrizi M, Hajiaghaee R, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2013;16:783\u20139.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"36_CR41","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1542\/peds.2011-0427","volume":"127","author":"ML McPheeters","year":"2011","unstructured":"McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011;127(5):e1312\u201321.","journal-title":"Pediatrics"},{"issue":"1","key":"36_CR42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/exnr.1997.6554","volume":"147","author":"A Stefani","year":"1997","unstructured":"Stefani A, Spadoni F, Bernardi G. Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol. 1997;147(1):115\u201322.","journal-title":"Exp Neurol"},{"issue":"2\u20133","key":"36_CR43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0014-2999(93)90147-A","volume":"235","author":"MW Debono","year":"1993","unstructured":"Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol. 1993;235(2\u20133):283\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"36_CR44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(00)00709-3","volume":"408","author":"G Sarro De","year":"2000","unstructured":"De Sarro G, Siniscalchi A, Ferreri G, Gallelli L, De Sarro A. NMDA and AMPA\/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA\/2 mice. Eur J Pharmacol. 2000;408(1):25\u201334.","journal-title":"Eur J Pharmacol"},{"key":"36_CR45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuropharm.2012.06.051","volume":"64","author":"GL Collingridge","year":"2013","unstructured":"Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, et al. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology. 2013;64:13\u201326.","journal-title":"Neuropharmacology"},{"issue":"8","key":"36_CR46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00702-008-0059-y","volume":"115","author":"G Rammes","year":"2008","unstructured":"Rammes G, Zieglgansberger W, Parsons CG. The fraction of activated N-methyl-d-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole. J Neural Transm. 2008;115(8):1119\u201326.","journal-title":"J Neural Transm"},{"issue":"2","key":"36_CR47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/10446670410001722096","volume":"11","author":"P Ashwood","year":"2004","unstructured":"Ashwood P, Van de Water J. A review of autism and the immune response. Clin Dev Immunol. 2004;11(2):165\u201374.","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"36_CR48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.20315","volume":"57","author":"DL Vargas","year":"2005","unstructured":"Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67\u201381.","journal-title":"Ann Neurol"},{"issue":"1","key":"36_CR49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijdevneu.2005.10.003","volume":"24","author":"PG Nelson","year":"2006","unstructured":"Nelson PG, Kuddo T, Song EY, Dambrosia JM, Kohler S, Satyanarayana G, et al. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci. 2006;24(1):73\u201380.","journal-title":"Int J Dev Neurosci"},{"issue":"2","key":"36_CR50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/pr.111.005108","volume":"64","author":"AE Autry","year":"2012","unstructured":"Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64(2):238\u201358.","journal-title":"Pharmacol Rev"},{"issue":"2\u20133","key":"36_CR51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3940(01)02098-5","volume":"310","author":"I Mizuta","year":"2001","unstructured":"Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett. 2001;310(2\u20133):117\u201320.","journal-title":"Neurosci Lett"},{"issue":"10","key":"36_CR52","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1096\/fj.02-0143fje","volume":"16","author":"R Katoh-Semba","year":"2002","unstructured":"Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002;16(10):1328\u201330.","journal-title":"FASEB J."},{"issue":"1","key":"36_CR53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/146608202317576507","volume":"3","author":"L Lacomblez","year":"2002","unstructured":"Lacomblez L, Bensimon G, Leigh PN, Debove C, Bejuit R, Truffinet P, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(1):23\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"3","key":"36_CR54","first-page":"1465","volume":"282","author":"GJ Sanderink","year":"1997","unstructured":"Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther. 1997;282(3):1465\u201372.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"36_CR55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2174\/1389450043345263","volume":"5","author":"R Berecz","year":"2004","unstructured":"Berecz R, Dorado P, De La Rubia A, Caceres MC, Degrell I, LLerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr Drug Targets. 2004;5(6):573\u20139.","journal-title":"Curr Drug Targets"},{"issue":"Suppl 4","key":"36_CR56","first-page":"15","volume":"69","author":"CJ McDougle","year":"2008","unstructured":"McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69(Suppl 4):15\u201320.","journal-title":"J Clin Psychiatry"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0036-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-013-0036-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0036-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T18:54:27Z","timestamp":1563303267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-013-0036-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,3]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s40272-013-0036-2","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,3]]}}}